MRMiguel Rivera

Miguel Rivera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Miguel Rivera has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Thyroid hormone biosynthesis machinery is altered in the ischemic myocardium: An epigenomic study

    by Carolina Gil-Cayuela, Esther Roselló-Lletí, Estefanía Tarazón, Ana Ortega, Juan Sandoval, Luis Martínez-Dolz, Juan Cinca, Esther Jorge, José Ramón González-Juanatey, Francisca Lago, et al.


  • Open Access

    ATP synthase subunit alpha and LV mass in ischaemic human hearts

    by Esther Roselló‐Lletí, Estefanía Tarazón, María G. Barderas, Ana Ortega, Maria Micaela Molina‐Navarro, Alba Martínez, Francisca Lago, Luis Martínez‐Dolz, Jose Ramón González‐Juanatey, Antonio Salvador, et al.

    Mitochondrial dysfunction plays a critical role in the development of ischaemic cardiomyopathy (ICM). In this study, the mitochondrial proteome in the cardiac tissue of ICM patients was analysed by quantitative differential electrophoresis (2D‐DIGE) and mass spectrometry (MS) for the first time to provide new insights into cardiac dysfunction in this cardiomyopathy. We isolated mitochondria from LV samples of explanted hearts of ICM patients (n = 8) and control donors (n = 8) and used a proteomic approach to investigate the variations in mitochondrial protein expression. We found that most of the altered proteins were involved in cardiac energy metabolism (82%). We focused on ATPA, which is involved in energy production, and dihydrolipoyl dehydrogenase, implicated in substrate utilization, and observed that these molecules were overexpressed and that the changes detected in the processes mediated by these proteins were closely related. Notably, we found that ATPA overexpression was associated with reduction in LV mass (r = −0.74, P < 0.01). We also found a substantial increase in the expression of elongation factor Tu, a molecule implicated in protein synthesis, and PRDX3, involved in the stress response. All of these changes were validated using classical techniques and by using novel and precise selected reaction monitoring analysis and an RNA sequencing approach, with the total heart samples being increased to 24. This study provides key insights that enhance our understanding of the cellular mechanisms related to the pathophysiology of ICM and could lead to the development of aetiology‐specific heart failure therapies. ATPA could serve as a molecular target suitable for new therapeutic interventions.


  • Open Access

    Differential Gene Expression of Cardiac Ion Channels in Human Dilated Cardiomyopathy

    by Maria Micaela Molina-Navarro, Esther Roselló-Lletí, Ana Ortega, Estefanía Tarazón, Manuel Otero, Luis Martínez-Dolz, Francisca Lago, José Ramón González-Juanatey, Francisco España, Pablo García-Pavía, et al.

    Dilated cardiomyopathy (DCM) is characterized by idiopathic dilation and systolic contractile dysfunction of the cardiac chambers. The present work aimed to study the alterations in gene expression of ion channels involved in cardiomyocyte function. Microarray profiling using the Affymetrix Human Gene® 1.0 ST array was performed using 17 RNA samples, 12 from DCM patients undergoing cardiac transplantation and 5 control donors (CNT). The analysis focused on 7 cardiac ion channel genes, since this category has not been previously studied in human DCM. SCN2B was upregulated, while KCNJ5, KCNJ8, CLIC2, CLCN3, CACNB2, and CACNA1C were downregulated. The RT-qPCR (21 DCM and 8 CNT samples) validated the gene expression of SCN2B (p < 0.0001), KCNJ5 (p < 0.05), KCNJ8 (p < 0.05), CLIC2 (p < 0.05), and CACNB2 (p < 0.05). Furthermore, we performed an IPA analysis and we found a functional relationship between the different ion channels studied in this work. This study shows a differential expression of ion channel genes involved in cardiac contraction in DCM that might partly underlie the changes in left ventricular function observed in these patients. These results could be the basis for new genetic therapeutic approaches.


  • Relación entre modelado miocárdico y función diastólica en pacientes con hipertensión esencial

    by Raquel Cortés, Esther Roselló-Lletí, Manuel Portolés, Luis Almenar, Luis Martínez-Dolz, Lilian Grigorian, Fernando García de Burgos, Nuria Carpena, Antonio Salvador, Vicente Bertomeu, et al.


  • Open Access

    Cardiac protein changes in ischaemic and dilated cardiomyopathy: a proteomic study of human left ventricular tissue

    by Esther Roselló‐Lletí, Jana Alonso, Raquel Cortés, Luis Almenar, Luis Martínez‐Dolz, Ignacio Sánchez‐Lázaro, Francisca Lago, Inmaculada Azorín, Jose R González Juanatey, Manuel Portolés, et al.

    The development of heart failure (HF) is characterized by progressive alteration of left ventricle structure and function. Previous works on proteomic analysis in cardiac tissue from patients with HF remain scant. The purpose of our study was to use a proteomic approach to investigate variations in protein expression of left ventricle tissue from patients with ischaemic (ICM) and dilated cardiomyopathy (DCM). Twenty‐four explanted human hearts, 12 from patients with ICM and 12 with DCM undergoing cardiac transplantation and six non‐diseased donor hearts (CNT) were analysed by 2DE. Proteins of interest were identified by mass spectrometry and validated by Western blotting and immunofluorescence. We encountered 35 differentially regulated spots in the comparison CNT versus ICM, 33 in CNT versus DCM, and 34 in ICM versus DCM. We identified glyceraldehyde 3‐phophate dehydrogenase up‐regulation in both ICM and DCM, and alpha‐crystallin B down‐regulation in both ICM and DCM. Heat shock 70 protein 1 was up‐regulated only in ICM. Ten of the eleven differentially regulated proteins common to both aetiologies are interconnected as a part of a same network. In summary, we have shown by proteomics analysis that HF is associated with changes in proteins involved in the cellular stress response, respiratory chain and cardiac metabolism. Although we found altered expression of eleven proteins common to both ischaemic and dilated aetiology, we also observed different proteins altered in both groups. Furthermore, we obtained that seven of these eleven proteins are involved in cell death and apoptosis processes, and therefore in HF progression.


  • Open Access

    MMP-2 and sTNF-R1 Variability in Patients with Essential Hypertension: 1-Year Follow-Up Study

    by Núria Carpena, Esther Roselló-Lletí, Jose R. Calabuig, Estefanía Tarazón, Jose R. González-Juanatey, Luis Martínez-Dolz, Antonio Salvador, Lilian Grigorian, Plácido Orosa, Manuel Portolés, et al.

    The aim of this study is to analyze MMP-2 and sTNF-R1 variability, potent predictors of cardiovascular events, in stable hypertensive patients during a 12-month followup. 234 asymptomatic patients (age 60±13, 136 male) out of 252 patients with essential hypertension were followed up. MMP-2 and sTNF-R1 were measured at baseline and after 12 months (stage I). To compare MMP-2 and sTNF-R1 levels over time interval, we used the statistical method of Bland-Altman. MMP-2 and sTNF-R1 reproducibility was good in our patients for the two intervals with a coefficient of reproducibility of 8.2% and 11.3%, respectively. The percentages of patients within 1.96 × standard deviation of the mean were 93.6% and 92.7%. An elevated coefficient of correlation was obtained for MMP-2, basal versus stage I (r=0.55, P<0.0001) and for sTNF-R1 (r=0.75, P<0.0001). There is good stability in MMP-2 and sTNF-R1 levels in a followup study of patients with stable hypertension. As a consequence, assessment of its concentrations may be a useful tool for monitoring the follow-up of these patients. Measured variations in MMP-2 and sTNF-R1 levels, exceeding 8.2% and 11.3%, respectively, may indicate an increase in cardiovascular risk, thus, could be used to optimizing treatment than blood pressure control alone.


  • Open Access

    Variability of NT-proBNP and Its Relationship with Inflammatory Status in Patients with Stable Essential Hypertension: A 2-Year Follow-Up Study

    by Esther Roselló-Lletí, Jose R. Calabuig, Pedro Morillas, Raquel Cortés, Luis Martínez-Dolz, Luis Almenar, Jose R. González-Juanatey, Catheline Lauwers, Antonio Salvador, Manuel Portolés, et al.

    The variability of NT-proBNP levels has been studied in heart failure, yet no data exist on these changes over time in hypertensive patients. Furthermore, studies on the relationship between natriuretic peptides and inflammatory status are limited. 220 clinically and functionally asymptomatic stable patients (age 59±13, 120 male) out of 252 patients with essential hypertension were followed up, and NT-proBNP was measured at baseline, 12 and 24 months. No differences in NT-proBNP were found with respect to the basal stage in the hypertrophic group, but significant changes were found in non-hypertrophic subjects. The reproducibility of NT-proBNP measurements was better in patients with hypertrophy than in the non-hypertrophic group for the three intervals (stage I-basal; stage II-stage I; stage II-basal) with a reference change value of 34%, 35% and 41%, respectively, in the hypertrophic group. A more elevated coefficient of correlation was obtained in the hypertrophic group than in patients without hypertrophy: basal versus stage I (r = 0.79, p35% in a 12-month follow-up and 41% in a 24-month follow-up, may indicate an increase in cardiovascular risk, and therefore implies adjustment in the medical treatment. In addition, this study shows a link between neurohormonal and inflammatory activation in these patients.


  • Open Access

    Impact of Cardiovascular Risk Factors and Inflammatory Status on Urinary 8-OHdG in Essential Hypertension

    by Esther Roselló-Lletí, F. G. D. Burgos, Pedro Morillas, Raquel Cortés, Luis Martínez-Dolz, Luis Almenar, Lilian Grigorian, Plácido Orosa, Manuel Portolés, Vicente Bertomeu, et al.

    Background:. The urinary concentrations of 8-hydroxy-2′-deoxyguanosine (8-OHdG) reflect the oxidation status of hypertensive subjects and it can be used for mo


  • Valor pronóstico de big endotelina-1 en pacientes con insuficiencia cardíaca y clase funcional moderadamente sintomática

    by Esther Roselló-Lletí, Miguel Rivera, Vicente Miró, Raquel Cortés, Luís Martínez-Dolz, Manuel Portolés

  • Open Access

    Inflammatory Activation and Left Ventricular Mass in Essential Hypertension

    by Esther Roselló-Lletí, Miguel Rivera, Luís Martínez-Dolz, Jose R. González Juanatey, Raquel Cortés, Alejandro Jordán, Pedro Morillas, Catheline Lauwers, Jose R. Calabuig, Isabel Antorrena, et al.

    Background. Inflammation is an independent risk factor for high blood pressure, and as a consequence inflammatory cytokines could be related with left